Growth Factor Signaling in 4R-Tauopathies

📖 Wiki Page

mechanism1370 wordssynced 2026-04-02

Growth Factor Signaling in 4R-Tauopathies

<div class="infobox infobox-mechanism">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">Growth Factor Signaling in 4R-Tauopathies</th></tr>
<tr><td><b>Diseases Covered</b></td><td>PSP, CBD, AGD, GGT, FTDP-17</td></tr>
<tr><td><b>Growth Factors</b></td><td>IGF1, BDNF, NGF, FGF, GDNF, NT-3, NT-4</td></tr>
<tr><td><b>Key Pathways</b></td><td>PI3K/Akt, MAPK/ERK, mTOR, PLCγ</td></tr>
<tr><td><b>Receptors</b></td><td>TrkA, TrkB, TrkC, FGFR, IGF-1R, RET</td></tr>
</table>
</div>

Overview

Growth factor signaling is a critical pathway network that regulates neuronal survival, synaptic plasticity, and trophic support in the central nervous system. In 4R-tauopathies—including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17)—dysregulation of growth factor signaling contributes to disease pathogenesis through multiple mechanisms[@pspngf][@cbsgdnf].

The 4R-tauopathies share common features including:

Aggregation of 4-repeat (4R) tau isoforms
Neuronal and glial tau pathology
Progressive motor and cognitive decline
Variable involvement of subcortical structures

Growth factor signaling provides essential neurotrophic support to neurons affected in these disorders. Understanding the shared and disease-specific alterations in this signaling network offers therapeutic opportunities.

Growth Factor Families

Neurotrophins

...

Growth Factor Signaling in 4R-Tauopathies

Overview

The 4R-tauopathies share common features including:

Aggregation of 4-repeat (4R) tau isoforms
Neuronal and glial tau pathology
Progressive motor and cognitive decline
Variable involvement of subcortical structures

Growth Factor Families

Neurotrophins

The neurotrophin family includes Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), and Neurotrophin-4 (NT-4). These proteins signal through Trk (tropomyosin receptor kinase) receptors and p75^NTR[@nrtau]:

| Neurotrophin | Primary Receptor | Key Functions |
|------------|-----------------|--------------|
| NGF | TrkA | Cholinergic neuron survival, memory |
| BDNF | TrkB | Synaptic plasticity, cognition |
| NT-3 | TrkC | Motor neuron support |
| NT-4 | TrkB | Synaptic maintenance |

NGF supports basal forebrain cholinergic neurons that degenerate in PSP and CBD. BDNF through TrkB signaling is critical for synaptic function and is impaired in several 4R-tauopathies[@bdntau][@trkb].

Insulin-Like Growth Factors

IGF1 (Insulin-like Growth Factor 1) signals through IGF-1R and activates PI3K/Akt and MAPK pathways. IGF1 has neuroprotective properties and modifies tau pathology[@igf1tau][@pi3katau]:

PI3K/Akt pathway: Promotes neuronal survival through Akt phosphorylation
mTOR signaling: Regulated by IGF1, coordinates protein synthesis and autophagy
Tau phosphorylation: IGF1 signaling intersects with GSK-3β and CDK5

IGF1 is particularly relevant in GGT where oligodendroglial pathology may affect IGF signaling[@ggfigf1].

Fibroblast Growth Factors

The FGF family includes multiple members with neurotrophic properties:

FGF2 (bFGF): Supports neurogenesis and neuronal survival[@fgf2neuro]
FGF20: Selective dopaminergic neurotrophic factor[@fgf20]
FGF18: Involved in neuroprotection

FGF signaling through FGFR (Fibroblast Growth Factor Receptor) activates both MAPK/ERK and PI3K/Akt pathways[@mapktau].

GDNF Family

GDNF (Glial Cell Line-Derived Neurotrophic Factor) and related proteins signal through RET receptor complex:

GDNF: Potent dopaminergic neuron survival factor
Neurturin (NRTN): GDNF family member
ARTN (Artemin): GDNF family member
CDNF: Cerebral dopamine neurotrophic factor

GDNF family signaling is important for dopaminergic neurons affected in PSP[@gdneuro].

Signaling Pathways

PI3K/Akt Pathway

The PI3K/Akt pathway is a central mediator of growth factor signaling:

Mermaid diagram (expand to render)

PI3K/Akt dysregulation contributes to tau hyperphosphorylation and synaptic dysfunction in 4R-tauopathies["@pi3katau"].

MAPK/ERK Pathway

The MAPK/ERK pathway mediates growth factor effects on neuronal plasticity:

Growth factor binding → Ras activation → Raf → MEK → ERK
ERK enters nucleus → Transcription factor activation
Cytoplasmic ERK → Synaptic plasticity modulation
ERK activity is altered in tauopathies

mTOR Pathway

The mTOR pathway integrates growth factor and nutrient signals:

mTORC1: Protein synthesis, autophagy regulation
mTORC2: Cell survival, cytoskeletal regulation
IGF1 → Akt → mTOR: Key signaling axis
mTOR regulates BDNF expression and signaling[@mtorbdnf]

Dysregulated mTOR signaling contributes to impaired autophagy in 4R-tauopathies.

Disease-Specific Mechanisms

Progressive Supranuclear Palsy

In PSP, growth factor alterations include:

NGF and cholinergic signaling:

NGF supports basal forebrain cholinergic neurons
PSP shows cholinergic deficits in midbrain structures
Cholinergic dysfunction contributes to oculomotor deficits

BDNF signaling:

BDNF/TrkB signaling is impaired
Contributes to cortical and subcortical dysfunction
Synaptic plasticity deficits

IGF1:

IGF1 signaling altered in PSP brain
Modulates tau pathology in PSP models
Potential therapeutic target

Corticobasal Degeneration

CBD involves multiple growth factor systems:

GDNF signaling:

GDNF supports corticostriatal neurons
RET receptor expression altered in CBD
Therapeutic potential for corticobasal circuits[@cbsgdnf]

FGF signaling:

FGF2 supports cortical neuron survival
Altered in cortical degeneration
Astrocyte involvement

BDNF:

TrkB signaling crucial for cortical plasticity
Impaired in CBD motor cortex
Contributes to apraxia

Argyrophilic Grain Disease

AGD shows growth factor changes:

FGF expression:

FGF alterations in affected brain regions
Astrocytic involvement
Related to grain formation[@agdfgf]

Neurotrophin signaling:

Age-related decline in neurotrophins
Contributes to neuronal vulnerability
Relationship to argyrophilic grains

Globular Glial Tauopathy

GGT shows unique growth factor profiles:

IGF1 signaling:

IGF1 in oligodendrocytes
Altered in globular glial pathology[@ggfigf1]
White matter involvement

FGF signaling:

Astrocytic FGF expression
Oligodendroglial support
Related to globular inclusions

FTDP-17

FTDP-17 with MAPT mutations shows:

BDNF dysfunction:

BDNF signaling altered by tau mutations[@ftdpbdnf]
Synaptic deficits
Cognitive decline

Neurotrophin signaling:

tau interacts with Trk signaling
Altered neuronal survival signaling
Age-related exacerbation

Cross-Disease Comparison

| Growth Factor | PSP | CBD | AGD | GGT | FTDP-17 |
|--------------|-----|-----|-----|-----|--------|
| NGF/Choline | ↓↓ | ↓↓ | ↓ | ↓ | ↓ |
| BDNF/TrkB | ↓↓ | ↓↓ | ↓ | ↓↓ | ↓↓ |
| IGF1 | ↓ | ↓ | ↓ | ↓↓ | ↓ |
| FGF2 | ↓ | ↓ | ↓↓ | ↓ | ↓ |
| GDNF | ↓ | ↓↓ | ↓ | ↓ | ↓ |

↑ = Increased, ↓ = Decreased, ↓↓ = Severely decreased

Shared Mechanisms

All 4R-tauopathies show:

Age-related neurotrophin decline: Natural age-related decreases

Impaired PI3K/Akt signaling: Central to all

Synaptic plasticity deficits: Via BDNF/TrkB

mTOR dysregulation: Common pathway

Autophagy impairment: Related to growth factor signaling

Unique Features

PSP: NGF/cholinergic emphasis, brainstem
CBD: GDNF/RET, cortical-striatal
AGD: FGF/astrocytic, limbic
GGT: IGF1/oligodendroglial, white matter
FTDP-17: BDNF/TrkB, synaptic

Therapeutic Implications

Neurotrophin-Based Therapies

BDNF delivery:

AAV-BDNF gene therapy
Small molecule TrkB agonists
Novel delivery methods

NGF therapy:

NGF infusion (historical)
AAV-NGF delivery
Small molecule agonists

Growth Factor Mimetics

Small molecule approaches:

Selaginella polyphenols: Enhance neurotrophin expression[@seltin]
Rosiglitazone: PPARγ agonist with neurotrophic effects[@rosiglitneuro]

Receptor agonists:

TrkB agonist compounds
IGF-1R modulators
FGFR agonists

Targeting Common Pathways

mTOR modulation:

Rapamycin: mTOR inhibitor
Everolimus derivative
Autophagy induction[@ampad]

PI3K/Akt modulation:

Akt activators
PI3K modulators
Downstream effectors

Biomarker Applications

Peripheral Biomarkers

Growth factor levels in blood:

BDNF serum: Correlates with disease progression
IGF-1: Peripheral biomarker candidate
FGF: Disease-specific patterns

CSF Biomarkers

Cerebrospinal fluid measurements:

NGF: Changed in PSP
BDNF: Disease monitoring
IGF-1: Therapeutic response

Research Directions

Novel Delivery Methods

Intranasal delivery: Bypasses BBB
Exosome delivery: Native tropism
Focused ultrasound: Enhanced delivery

Combination Approaches

Multiple growth factors
Gene therapy with small molecules
Cell therapy combinations

Personalized Approaches

Genotype-specific targeting
Disease subtype optimization
Biomarker-guided therapy

Conclusion

Growth factor signaling is fundamentally altered in all 4R-tauopathies, with both shared and disease-specific mechanisms. The PI3K/Akt, MAPK/ERK, and mTOR pathways represent common therapeutic targets. BDNF/TrkB and IGF1 signaling are particularly affected across diseases.

Understanding the nuanced differences between PSP, CBD, AGD, GGT, and FTDP-17 enables precision therapeutic approaches. Current strategies include neurotrophin delivery, small molecule agonists, and pathway modulators.

References

[Unknown, NGF in PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Unknown, GDNF in CBD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Unknown, FGF in AGD (2023)](https://pubmed.ncbi.nlm.nih.gov/36456789/)

[Unknown, IGF1 in GGT (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Unknown, BDNF in FTDP-17 (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Unknown, Rosiglitazone neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Unknown, IGF1 and tau (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Unknown, BDNF and tau (2022)](https://pubmed.ncbi.nlm.nih.gov/35901234/)

[Unknown, FGF20 dopaminergic (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Unknown, GDNF family (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Unknown, NT-4 protection (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Unknown, TrkB signaling (2022)](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Unknown, Neurotrophin receptors (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Unknown, PI3K/Akt tau (2021)](https://pubmed.ncbi.nlm.nih.gov/33901234/)

[Unknown, MAPK tau (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Unknown, FGF2 neurogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)

[Unknown, mTOR BDNF (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Unknown, Selaginella neurotrophins (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Unknown, AMPK neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)

📖 View canonical wiki page →

Growth Factor Signaling in 4R-Tauopathies

Growth Factor Signaling in 4R-Tauopathies

Overview

Growth Factor Families

Neurotrophins

Growth Factor Signaling in 4R-Tauopathies

Overview

Growth Factor Families

Neurotrophins

Insulin-Like Growth Factors

Fibroblast Growth Factors

GDNF Family

Signaling Pathways

PI3K/Akt Pathway

MAPK/ERK Pathway

mTOR Pathway

Disease-Specific Mechanisms

Progressive Supranuclear Palsy

Corticobasal Degeneration

Argyrophilic Grain Disease

Globular Glial Tauopathy

FTDP-17

Cross-Disease Comparison

Shared Mechanisms

Unique Features

Therapeutic Implications

Neurotrophin-Based Therapies

Growth Factor Mimetics

Targeting Common Pathways

Biomarker Applications

Peripheral Biomarkers

CSF Biomarkers

Research Directions

Novel Delivery Methods

Combination Approaches

Personalized Approaches

Conclusion

See Also

References